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ABSTRACT
Differential display PCR (DD-PCR) is an mRNA finger-
printing technique to identify differentially expressed
genes by comparative display of arbitrarily amplified
cDNA subsets. This attractively simple screening
method was, however, followed by a labour intensive
multistep identification procedure for DD-PCR products.
In this report we demonstrate for the mouse mast cell
protease 2 (MMCP-2) and the cytotoxic T-lymphocyte
associated gene transcript CTLA-1 a streamlined
approach by (i) direct cycle sequencing with the
upstream differential display (DD) primer, followed by
(ii) the PCR based generation of an antisense northern
probe with the downstream anchor primer.
We have applied differential display PCR (DD-PCR; 1) to a
murine tumor model in which transduction of the v-H-ras
oncogene into IL-3 dependent non tumorigenic PB-3c mast cells
gave rise to IL-3 autocrine tumors with an increased IL-3 mRNA
stability. IL-3 mRNA expression from this autocrine tumor could
be suppressed by somatic cell fusion with precursor cells implying
a recessive alteration (2–4).
Culturing of the precursor cell PB-3c clone 20, the tumor line
V2D1 and the hybrid 20/V2D1 has been described previously (3).
Total cytoplasmic RNA was isolated from each cell line according
to Gough (5) followed by DNAse I digestion (6). Integrity of the
RNA was checked by agarose formaldehyde gel electrophoresis.
Comparison of precursor PB-3c clone 20 with the tumor V2D1
cells was performed by the DD-PCR technique essentially as
described by Bauer et al. (7). For reverse transcription of an mRNA
subset, 0.2 µg of RNA was mixed first with 50 pmol anchor primer,
dT12VN, (V representing A, G or C and N being A, C, G or T) in
a volume of 7 µl, kept for 10 min at 65C and immediately put on
ice. Following addition of 300 U MMLV- reverse transcriptase
(Gibco Life Technologies) it was incubated for 1 h at 37C in
reverse transcription buffer (40 mM KCl, 50 mM Tris–HCl pH 8.3,
6 mM MgCl2) containing 20 µM dNTP, 10 mM DTT and 40 U
RNAsin (Boehringer) in a total volume of 20 µl. After 5 min
at 95C the cDNA was stored at –20C until use in DD-PCR.
DD-PCR was performed with 2 µl of 20 µl cDNA in a Perkin-
Elmer Cetus thermal cycler 480 using PCR buffer (10 mM Tris–HCl
pH 8.3, 50 mM KCl), 2.5 U AmpliTaq DNA Polymerase (Perkin
Elmer), 1.25 mM MgCl2, 4 µM dNTP, 1 µCi [α-32P]dCTP, 2.5 µM
of the respective downstream anchor primer dT12VN and 0.5 µM
of one upstream DD-primer from the set of 26 decameric
oligonucleotide primers according to Bauer et al. (7) using the
following conditions: 5 min incubation at 95C followed by 40
cycles of 94C for 30 s, 40C for 2 min and 72C for 30 s. PCR
product (3 µl) was added to 2 µl sample buffer and incubated at
95C for 5 min. The PCR products were resolved on a 6%
polyacrylamide–7 M urea gel in 1× TBE buffer (89 mM Tris,
89 mM boric acid, 0.025 mM EDTA). The gel was dried and
analysed by a PhosphorImager  (Molecular Dynamics) (Fig. 1A
and B).
The differentially displayed bands were cut out from a wet
polyacrylamide gel after localisation on a X-ray film. The DNA
was eluted with the QIAEX II Gel Extraction Kit (QIAGEN)
according to the protocol of the supplier. With 6 µl of the 20 µl
eluate the DD-PCR was repeated without labelled dCTP but with
100 µM dNTP. The reamplification product was resolved on a 2%
TBE agarose gel, stained with ethidium bromide (Fig. 1C),
recovered with the QIAEX II Gel Extraction Kit and resuspended
in 20 µl ddH2O. This amplicon was used for (i) direct sequencing
and (ii) generation of a labelled probe.
Direct sequence determination with the upstream DD-primer
was done on the ABI 310 genetic analyzer using the ABI
PRISM Dye Terminator Cycle Sequencing Ready Reaction
Kit (Perkin Elmer). Gel purified reamplification product (6 µl)
was mixed with 32 pmol upstream DD-primer and 8 µl terminator
ready reaction mix in a total volume of 20 µl. We modified the
cycling conditions for the sequencing with short decameric
DD-primers as follows: 25 cycles of 96C for 30 s, 40C for 15 s
and 60C for 4 min (480 Perkin Elmer Cetus Thermal Cycler).
The samples were prepared for the sequence analysis as described
by the supplier using the ethanol precipitation protocol to remove
unincorporated dye terminators (Fig. 1D and E). Sequence
determination of 100–150 nt allowed the search in the gene bank
and direct cycle labelling for northern analysis.
For northern analysis, an antisense probe was generated by
cycle labelling with the downstream anchor primer. Gel purified
reamplification product as template (5 µl) was incubated with
PCR buffer (10 mM Tris–HCl pH 8.3, 50 mM KCl), 25 pmol of
the respective T12VN, 0.04 mM dNTP, 50 µCi [α-32P]dCTP and
2.5 U AmpliTaq DNA Polymerase  (Perkin Elmer) in a total
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Figure 1.  Illustration of the direct cycle sequencing and cycle labelling strategy for DD-PCR products with two differentially expressed genes as described in the text.
volume of 100 µl (5 min at 95C, 40 cycles of 1 min at 96C, 2 min
at 35C, 1 min at 72C). The labelled product was extracted with
the QIAquick PCR Purification Kit (QIAGEN) and the integrity
and size of the probe was visualised on a 6% polyacrylamide–7 M
urea gel (Fig. 1F). Hybridisation was done with 6 × 106 c.p.m. in
a volume of 5 ml. Northern blots were prepared as described
previously with 20 µg RNA per lane (8). The filters were
prehybridised in 5 ml prewarmed hybridisation solution (50%
formamide, 5× SSC, 5× Dehnhardt’s solution, 5 mM EDTA, 0.5
mg/ml yeast tRNA, 0.1 mg/ml heparin, 0.2% SDS) for 2 h at 45C
in a rotating hybridisation oven. After adding the heat denatured
probe, the filter was hybridised overnight. Washing was done
twice with prewarmed 2× SSC, 0.1% SDS at 55C for 30 min.
The filter was analysed by a PhosphorImager (Fig. 1G and H).
To illustrate this approach we show the identification of one
upregulated (Fig. 1A) and one downregulated band (Fig. 1B)
which were found during DD-PCR comparison of the tumor line
V2D1 and the precursor line PB-3c clone 20 with the following
primer pairs: anchor primer T12CG (T2) versus DD-primer D13
(GTTTTCGCAG) and anchor primer T12CC (T4) versus DD-
primer D5 (GGAACCAATC). As shown in Figure 1D and E, the
reamplified DD-PCR products could be directly sequenced using
DD-primers D13 or D5, respectively. The sequences could be
read over a stretch of more than 100 nt in sense direction at the
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end of which the complementary sequence to the respective
downstream anchor primer could be identified (Fig. 1E).
Comparison of both sequences with entries in GenBank/EMBL/
PDB databases identified a 100% match with the mouse mast cell
protease 2 (MMCP-2) (9) and the mouse cytotoxic T lymphocyte
associated gene transcript CTLA-1 (10), respectively. Differential
expression of both genes was confirmed by northern analysis
using the antisense probe generated from the sequenced fragments.
MMCP-2 is expressed in the tumor cell V2D1, but is not
expressed in the precursor cell. The expression of MMCP-2 in the
hybrid 20/V2D1 is at least 10 times downregulated compared to
the tumor cell (Fig. 1G). Ethidium bromide stained gels served as
loading controls. Initially identified in Ki-ras transformed mast
cells, MMCP-2 is a marker for intermediate differentiation stages
between the bone marrow derived and the fully mature mast cells
(9). In contrast CTLA-1 is expressed in the precursor cell PB-3c
clone 20 but is missing in the tumor V2D1 and in the hybrid cell
(Fig. 1H). This serine protease belongs to the granzyme group
predominantly expressed in cytotoxic T-cells but it has also been
found in mast cells, yet is lacking in the mastocytoma P815 (10).
Direct cycle sequencing with decameric DD-primers and direct
generation of an antisense probe by cycle labelling is a streamlined
approach to identify a differentially expressed gene represented
by a DD-PCR fragment. It avoids the conventionally used labour
intensive subcloning procedure, which consisted of ligation into
a plasmid vector, transformation of Escherichia coli cells and
identification of a clone corresponding to the differentially
expressed gene before the sequence could be determined. The
costs for the modification of the DD-PCR product by primer
extension in order to use classical sequencing primers for direct
sequencing can also be saved (11). In the optimal case the
sequence and the confirmation of differential expression can be
obtained within 3 days. If the reamplified DD-PCR product
consists of more than one template or was primed by the same
primer on both sides subcloning cannot be avoided, which was the
case in ∼20% of the 30 differentially displayed bands detected
during our systematic DD-PCR screening. Furthermore, the direct
identification of DD-PCR products generated with different primer
combinations but arising from the same differentially expressed
gene avoids unnecessary further analysis. If northern hybridisation
does not yield a signal due to low abundance of the transcript, the
sequence may provide the information for other more sensitive
methods to confirm differential expression.
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